|Year : 2011 | Volume
| Issue : 2 | Page : 176-179
Second transurethral resection in T1G3 bladder tumors - Selectively avoidable?
Francis S Katumalla1, Antony Devasia1, Ramani Kumar2, Santosh Kumar1, Ninan Chacko1, Nitin Kekre1
1 Department of Urology, Christian Medical College, Vellore, Tamil Nadu, India
2 Department of Pathology, Christian Medical College, Vellore, Tamil Nadu, India
|Date of Web Publication||8-Jul-2011|
Department of Urology, Christian Medical College, Vellore - 632 004, Tamil Nadu
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Aim : To assess the need of a second transurethral resection (TUR) in select T1G3 bladder tumor patients.
Materials and Methods : All the pT1G3 bladder tumors diagnosed during the period between January 2005 and December 2008 were included. Second TUR was routinely performed in all the pT1G3 bladder tumors within 4-6 weeks. Fifty out of the 68 patients with T1G3 underwent a second TUR and were retrospectively reviewed. The primary bladder lesions were grouped as solitary papillary, multiple papillary and sessile lesions. Statistical analysis was performed using STATA version 11 (STATA Corp., Texas, USA).
Results : Forty percent (n = 20) of the lesions were solitary papillary, 48% (n = 24) were multiple papillary and 12% (n = 6) were sessile lesions. All our resections had muscularis propria sampled at the end of the resection and separately sent for histopathological examination (HPE), which showed them to be tumor free. Thirty-six percent of patients had residual disease at the second resection and 4% were upstaged. Ninety-five percent of the patients (n = 19) with solitary papillary lesions did not have any residual disease and 50% (n = 12) of the multiple papillary and 83.3% (n = 5) of the sessile group had residual disease at the second TUR.
Conclusions : Patients with T1G3 tumors do not represent a homogenous group. Second TUR is recommended in patients with high-grade T1 urothelial bladder carcinoma as it identifies residual disease and invasive disease. Solitary papillary lesions may be the only group where the need for the second TUR is questionable.
Keywords: Bladder cancer, high grade, transurethral resection
|How to cite this article:|
Katumalla FS, Devasia A, Kumar R, Kumar S, Chacko N, Kekre N. Second transurethral resection in T1G3 bladder tumors - Selectively avoidable?. Indian J Urol 2011;27:176-9
|How to cite this URL:|
Katumalla FS, Devasia A, Kumar R, Kumar S, Chacko N, Kekre N. Second transurethral resection in T1G3 bladder tumors - Selectively avoidable?. Indian J Urol [serial online] 2011 [cited 2020 Feb 19];27:176-9. Available from: http://www.indianjurol.com/text.asp?2011/27/2/176/82833
| Introduction|| |
T1G3 bladder cancer has a variable and unpredictable biologic potential.  Though noninvasive, the biological behavior of these tumors is similar to that of muscle invasive transitional cell carcinoma (TCC).  Factors predicting the poor prognosis of T1G3 tumors are multiplicity of tumors, high grade, size > 3 cm, sessile pattern, associated carcinoma insitu (CIS) and early recurrence after primary transurethral resection (TUR). ,, TUR of bladder tumors and intravesical therapy is now accepted as the standard of care for T1G3 tumors. The primary TUR may leave residual disease, more so in multiple tumors, increasing the risk of early tumor recurrence and stage progression even after intravesical therapy.  A second-look TUR of T1G3 tumors has multiple benefits - to eradicate the residual disease, identify the early recurrence , and avoid potential understaging, resulting in inadequate treatment. 
A second TUR increases the cost, morbidity and delays intravesical therapy. After a satisfactory primary resection with adequate muscle in the specimen, is a second TUR necessary? The objective of this analysis was to assess the relevance of second TUR in T1G3 bladder tumors in the Indian scenario and to identify the subgroup where a second TUR may be avoided.
| Materials and Methods|| |
All the pT1G3 bladder tumors diagnosed primarily during the period between January 2005 and December 2008 were included. In all subjects, after complete resection of the tumor macroscopically during the primary resection, deeper tissue with muscle was resected and sent separately for histopathological examination (HPE). All the patients had 40 mg of intravesical Mitomycin instilled at the end of the resection. The pathologist's report about the presence of uninvolved muscularis propria in the specimen was mandatory for inclusion in the study. Second TUR was routinely performed in all the pT1G3 bladder tumors within 4-6 weeks. All patients diagnosed to have T1G3 were planned for second TUR, except those with extensive disease involving almost the entire bladders, who were offered radical cystectomy. Resection was performed at the previous resection scar sites as documented by the earlier surgery records and also at the doubtful areas. The video-assisted resections were supervised or carried out by a consultant.
Statistical analysis was performed using STATA version 11 (STATA Corp., TX, USA). Fisher exact confidence intervals were drawn for relative risk estimates and calculated with a 95% confidence interval.
| Results|| |
There were a total of 535 patients with TCC bladder, who underwent transurethral resection of bladder tumor (TURBT) during this period. Sixty-eight of them were detected to have pT1G3 bladder tumors and were planned for a second TUR. Five had extensive disease involving almost the whole of the bladder and were advised radical cystectomy. Thirteen patients were unwilling for another operative procedure. These 18 were excluded from the analysis. Fifty patients underwent a second TUR. The mean age was 57.5 years (range 31-76 years) and four were women.
[Table 1] shows the demographics and the characteristics of the lesions of all the 50 patients who underwent second resection. The primary lesions were grouped as solitary papillary, multiple papillary and sessile lesions. Of the six sessile lesions, one was a multiple sessile tumor. At the second resection, 18 (36%) had residual disease. Of these, 10 (20%) had gross residual disease. More importantly, even in the absence of gross residual tumor, a second resection identified eight patients (44%) with a positive histopathology.
Solitary papillary lesions did not have any gross residual disease in the second TUR. Most of the gross residual disease was seen in patients with primary multiple papillary lesions and one patient from the sessile group had a gross residual disease [Table 2].
The characteristics of the primary lesion with the pathology found in the second resection were compared [Table 3]. Histopathologically, these were categorized as no residual disease, same stage tumors, lower stage tumors, CIS and higher staged lesions. Of the 20 patients with solitary papillary lesions, 19 (95%) did not have any residual disease in the second TUR and one had a lower stage disease. Half of the patients with primary multiple papillary lesions were free of tumor at the second resection. One-third of the patients had the same stage tumor and two had upstaging of the disease. In the sessile group with residual disease, the same stage was seen in 84%.
Sessile tumors had 16.67 times greater risk of residual disease as compared to solitary papillary lesions (RR 16.67, 95% CI 2.39-116.37) and 1.66 times greater risk of residual disease as compared to multiple papillary tumors (RR 1.66, 95% CI 0.97-2.86). When multiple papillary lesions were compared to solitary papillary lesions, there was a 10-fold increase in risk of residual disease (RR 10, 95% CI 1.42-70.41). The residual disease in the sessile and multiple papillary lesions was statistically significant when compared to the solitary papillary lesions.
| Discussion|| |
TURBT is the initial step in the management of bladder cancer. A technically complete primary resection is warranted for accurate pathological staging and grading of the tumor. After complete resection of all the visible tumors, deep muscle is resected separately for histopathology. If the resected specimen has no muscle, there is a potential for understaging T1 tumors. In high grade tumors, second TUR plays a vital role. It is meant to detect and clear residual tumor, and in cases of upstaging, it helps to plan appropriate treatment. Detection of tumor at the second resection indicates poor prognosis. Gross residual tumors were seen in 20% of our study population. Ninety percent of the gross residual lesions were seen in those with primary multiple papillary lesions. Second TUR also proved reduction of early recurrence in high grade T1 tumors from 63 to 26%.  At the end of the first, third and fifth year, the recurrence free survival was 82%, 65% and 59%, respectively, in the patients who underwent a second TUR when compared to 57%, 37% and 32%, respectively, in the patients who did not undergo the second resection. 
Tumor architecture, papillary or sessile, and multifocality of these lesions are important prognostic factors for recurrence and progression of the disease. A solitary papillary lesion is considered to be a good prognostic factor as against multiple papillary and sessile lesions.  In our series, among those with solitary papillary lesions, one had a lower stage residual disease and 95% did not have any residual disease in the second resection. Perhaps this is the subgroup that is least likely to benefit from a second resection. Multiple papillary lesions and the sessile lesions had significant residual disease in the second resection. Fifty percent of the multiple papillary lesions and nearly 84% of the sessile lesions had residual disease. Both the patients who had upstaging of the disease had primary multiple papillary lesions.
The important factor here is the complete primary resection of the bladder tumor. Presence of the uninvolved muscularis propria in the resected specimen is the only identification for a complete resection.  Retrospective studies have shown that residual disease can be seen in up to 68% cases.  These high rates may also have been due to the fact that no muscle was present in many of the primary TUR specimens. Forty-nine percent of T1 lesions without muscle in the resected specimen were understaged when compared to only 14% with muscle in the resected specimen.  Understaging was reported in 64% of T1 tumors when muscle was absent in the specimen versus 30% when it was present.  All our resections had muscularis propria sampled at the end of the resection and separately sent for HPE, which showed them to be tumor free. This can explain why only 4% of our patients were upstaged at the second resection.
Another factor is the invasion of lamina propria superficial to the muscularis mucosa (T1a) which is considered a good prognostic factor as against the lamina propria deeper to muscularis mucosa.  Questions have been raised whether a second resection is really necessary in a well-performed initial resection of high-grade T1 solitary papillary lesions with only superficial invasion of lamina propria (T1a) with negative deep muscle biopsy, especially when intravesical therapy is planned. 
A comparison of similar studies is shown in [Table 4]. Emphasis was not given to complete primary resection with curative intent in many of them. One series had muscle in only 63% of the primary TURBT specimens.  In another series, though the presence of muscularis propria was not mentioned in the primary TURBT, 72% of the solitary lesions were tumor free at re-resection.  None had muscle in the resected specimen in another series, where 42 T1G3 patients underwent primary TURBT.  The primary characteristic of the lesion, which is an important prognostic factor, was also not considered in many of these studies.
We recognize the limitations of this study, viz., a small study group and also not considering factors like the size of the lesion and depth of lamina propria involved.
| Conclusions|| |
There is a need to improve the risk stratification to optimize the treatment of high-grade T1 disease. With the available present scientific data, second resection is recommended in all patients with high-grade T1 urothelial bladder carcinoma and it does identify residual disease and invasive disease. Patients with T1G3 tumors do not represent a homogenous group. Isolated solitary papillary lesions may be the only group where the need for the second TUR can be avoided. Is a second TUR really necessary in a well-performed initial resection of high-grade T1 solitary papillary lesions with only superficial invasion of lamina propria (T1a) with negative deep muscle biopsy? A well-designed multicentric prospective study with a large cohort assessing various risk factors of high-grade T1 lesions is necessary to determine the subgroups, if any, where a second TUR can be avoided.
| References|| |
|1.||Soloway MS, Lee CT, Steinberg GD, Ghandi AA, Jewett MA. Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 2007;25:338-40. |
|2.||Masood S, Sriprasad S, Palmer JH, Mufti GR. T1G3 bladder cancer - Indications for early cystectomy. Int Urol Nephrol 2004;36:41-4. |
|3.||Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy. J Urol 2007;177:75-9. |
|4.||Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1194-8. |
|5.||Borkowski A. Superficial bladder cancer T1G3: The choice of treatment. BJU Int 2002;89:623-7. |
|6.||Schips L, Augustin H, Zigeuner RE, Gallé G, Habermann H, Trummer H, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-3. |
|7.||Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early? J Urol 2010;165:808-10. |
|8.||Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002;60:822-5. |
|9.||Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial. J Urol 2006;175:1641-4. |
|10.||Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial. Eur Urol 2010;58:185-90. |
|11.||Serretta V, Ruggirello A, Dispensa N, Allegro R, Aragona F, Melloni D. Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumours selected for conservative treatment. J Urol 2008;180:886-90. |
|12.||Babjuk M. Second resection for non-muscle-invasive bladder carcinoma: Current role and future perspectives. Eur Urol 2010;58:191-2. |
|13.||Orsola A, Cecchini L, Raventos CX, Trilla E, Planas J, Landolfi S, et al. Risk factors for positive findings in patients with high grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacilli Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int 2010;105:202-7. |
|14.||Herr HW: The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol 1999;162:74-6. |
|15.||Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical understaging of high risk non muscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-3. |
|16.||Orsola A, Trias I, Ravento´s CX, Espanlo I, Cecchini L, Bucar S, et al. Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231-8. |
|17.||Orsola A, Cecchini L, Morote J. Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303-14. Eur Urol 2009;55:e15-16. |
|18.||Dalbagni G, Vora K, Kaag M, Cronin A, Bochner B, Donat SM. et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. Eur Urol 2009;56:903-10. |
[Table 1], [Table 2], [Table 3], [Table 4]